Tags

Type your tag names separated by a space and hit enter

Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions.
Am J Physiol Endocrinol Metab. 2007 Sep; 293(3):E697-704.AJ

Abstract

Acylated and unacylated ghrelin (AG and UAG) are gut hormones that exert pleiotropic actions, including regulation of insulin secretion and glucose metabolism. In this study, we investigated whether AG and UAG differentially regulate portal and systemic insulin levels after a glucose load. We studied the effects of the administration of AG (30 nmol/kg), UAG (3 and 30 nmol/kg), the ghrelin receptor antagonist [D-Lys(3)]GHRP-6 (1 micromol/kg), or various combinations of these compounds on portal and systemic levels of glucose and insulin after an intravenous glucose tolerance test (IVGTT, d-glucose 1 g/kg) in anesthetized fasted Wistar rats. UAG administration potently and dose-dependently enhanced the rise of insulin concentration induced by IVGTT in the portal and, to a lesser extent, the systemic circulation. This UAG-induced effect was completely blocked by the coadministration of exogenous AG at equimolar concentrations. Similarly to UAG, [D-Lys(3)]GHRP-6, alone or in combination with AG and UAG, strongly enhanced the portal insulin response to IVGTT, whereas exogenous AG alone did not exert any further effect. Our data demonstrate that, in glucose-stimulated conditions, exogenous UAG acts as a potent insulin secretagogue, whereas endogenous AG exerts a maximal tonic inhibition on glucose-induced insulin release.

Links

Publisher Full Text

Authors+Show Affiliations

Gauna C
Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. c.gauna@erasmus.nl
Kiewiet RM
No affiliation info available
Janssen JA
No affiliation info available
van de Zande B
No affiliation info available
Delhanty PJ
No affiliation info available
Ghigo E
No affiliation info available
Hofland LJ
No affiliation info available
Themmen AP
No affiliation info available
van der Lely AJ
No affiliation info available

MeSH

AcetylationAnimalsBlood GlucoseDose-Response Relationship, DrugDrug CombinationsGhrelinGlucose Tolerance TestInsulinMaleMetabolic Clearance RateOligopeptidesPeptide HormonesRatsRats, WistarReceptors, G-Protein-CoupledReceptors, Ghrelin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17578884

Citation

Gauna, Carlotta, et al. "Unacylated Ghrelin Acts as a Potent Insulin Secretagogue in Glucose-stimulated Conditions." American Journal of Physiology. Endocrinology and Metabolism, vol. 293, no. 3, 2007, pp. E697-704.
Gauna C, Kiewiet RM, Janssen JA, et al. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab. 2007;293(3):E697-704.
Gauna, C., Kiewiet, R. M., Janssen, J. A., van de Zande, B., Delhanty, P. J., Ghigo, E., Hofland, L. J., Themmen, A. P., & van der Lely, A. J. (2007). Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. American Journal of Physiology. Endocrinology and Metabolism, 293(3), E697-704.
Gauna C, et al. Unacylated Ghrelin Acts as a Potent Insulin Secretagogue in Glucose-stimulated Conditions. Am J Physiol Endocrinol Metab. 2007;293(3):E697-704. PubMed PMID: 17578884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. AU - Gauna,Carlotta, AU - Kiewiet,Rosalie M, AU - Janssen,Joop A M J L, AU - van de Zande,Bedette, AU - Delhanty,Patric J D, AU - Ghigo,Ezio, AU - Hofland,Leo J, AU - Themmen,Axel P N, AU - van der Lely,Aart Jan, Y1 - 2007/06/19/ PY - 2007/6/21/pubmed PY - 2007/10/25/medline PY - 2007/6/21/entrez SP - E697 EP - 704 JF - American journal of physiology. Endocrinology and metabolism JO - Am J Physiol Endocrinol Metab VL - 293 IS - 3 N2 - Acylated and unacylated ghrelin (AG and UAG) are gut hormones that exert pleiotropic actions, including regulation of insulin secretion and glucose metabolism. In this study, we investigated whether AG and UAG differentially regulate portal and systemic insulin levels after a glucose load. We studied the effects of the administration of AG (30 nmol/kg), UAG (3 and 30 nmol/kg), the ghrelin receptor antagonist [D-Lys(3)]GHRP-6 (1 micromol/kg), or various combinations of these compounds on portal and systemic levels of glucose and insulin after an intravenous glucose tolerance test (IVGTT, d-glucose 1 g/kg) in anesthetized fasted Wistar rats. UAG administration potently and dose-dependently enhanced the rise of insulin concentration induced by IVGTT in the portal and, to a lesser extent, the systemic circulation. This UAG-induced effect was completely blocked by the coadministration of exogenous AG at equimolar concentrations. Similarly to UAG, [D-Lys(3)]GHRP-6, alone or in combination with AG and UAG, strongly enhanced the portal insulin response to IVGTT, whereas exogenous AG alone did not exert any further effect. Our data demonstrate that, in glucose-stimulated conditions, exogenous UAG acts as a potent insulin secretagogue, whereas endogenous AG exerts a maximal tonic inhibition on glucose-induced insulin release. SN - 0193-1849 UR - https://www.unboundmedicine.com/medline/citation/17578884/Unacylated_ghrelin_acts_as_a_potent_insulin_secretagogue_in_glucose_stimulated_conditions_ L2 - https://journals.physiology.org/doi/10.1152/ajpendo.00219.2007?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓26]

Related Citations

More